The Role of Peptides in Muscle Recovery

How peptides are thought to help recovery

Lifters use two groups of peptides for recovery. Growth hormone secretagogues such as ipamorelin and GHRP-2 prompt the pituitary to release growth hormone, which raises IGF-1. Repair peptides like BPC-157 and TB-500 are said to act on damaged tissue directly. As of October 2026, no controlled human trial has tested either group for recovery after training.

What the evidence shows

BPC-157: emerging evidence

A 2025 systematic review of BPC-157 in sports medicine found 36 studies, 35 of them preclinical. In rodent injury models it improved muscle and tendon healing, which the authors link to angiogenesis and reduced inflammation. Human data are limited to a few small uncontrolled reports, none involving training. The review found no clinical safety data.

TB-500: preliminary evidence

TB-500 is often sold as thymosin beta-4. Anti-doping chemists identified it as Ac-LKKTETQ, a 7-residue fragment of the 43-residue protein. As of October 2026, FDA says it has found no human exposure data for the fragment. Human trials of full-length thymosin beta-4 don't apply to it, so recovery claims rest on animal and cell work.

GH secretagogues: moderate evidence for ipamorelin

These compounds reliably raise growth hormone. In a small IV study in healthy men, ipamorelin produced one GH pulse per dose, with a half-life of about 2 hours. Its only efficacy trial, a Phase 2 study in 117 adults after bowel surgery, missed its main endpoint. A rise in GH may not carry over to function either: in a 2-year trial of MK-677, an oral non-peptide secretagogue, older adults gained fat-free mass but not strength.

Timing and doses as users report them

Timing advice comes from community guides, not trials. Users commonly describe a bedtime dose of ipamorelin, often 100-300 mcg with Mod GRF 1-29 (CJC-1295 without DAC), to match the overnight GH pulse. Some add a dose after training. No study has compared these schedules; the trials used IV infusions, such as 0.03 mg/kg twice daily after surgery.

For BPC-157, users commonly report 250-500 mcg a day by subcutaneous injection, sometimes split in two. TB-500 reports vary more. Vendor guidance lists 2-2.5 mg twice weekly for 4-6 weeks, while forum users describe 0.5-2 mg daily or every other day, or 2-5 mg twice weekly. Neither has a tested human dose, and no controlled study has combined them (see peptide stacking protocols).

What else to weigh

Gray-market vials vary in purity, as our guide to peptide sourcing and quality control explains. For tested athletes, WADA's 2026 Prohibited List bans BPC-157 (S0) and TB-500 (S2.3) at all times. Ipamorelin and GHRP-2 fall under S2.2.4, also banned year-round (see peptides in competitive sports).